| pubmed-article:16855011 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16855011 | lifeskim:mentions | umls-concept:C0346647 | lld:lifeskim |
| pubmed-article:16855011 | lifeskim:mentions | umls-concept:C1519043 | lld:lifeskim |
| pubmed-article:16855011 | lifeskim:mentions | umls-concept:C1519810 | lld:lifeskim |
| pubmed-article:16855011 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:16855011 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:16855011 | pubmed:dateCreated | 2006-8-28 | lld:pubmed |
| pubmed-article:16855011 | pubmed:abstractText | We conducted a Phase I/II study to evaluate the local efficacy and toxicity of hyperfractionated accelerated radiotherapy (HART) combined with 5-fluorouracil (5-FU) and cisplatin (CDDP) in patients with unresectable advanced pancreatic cancer. | lld:pubmed |
| pubmed-article:16855011 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16855011 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16855011 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16855011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16855011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16855011 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16855011 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16855011 | pubmed:issn | 0368-2811 | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:SakonMasatoM | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:NaganoHiroaki... | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:NakamoriShoji... | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:DonoKeizoK | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:UmeshitaKojiK | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:MondenMoritoM | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:InoueTakehiro... | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:TanakaEiichiE | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:InoueToshihik... | lld:pubmed |
| pubmed-article:16855011 | pubmed:author | pubmed-author:TsujieMasanor... | lld:pubmed |
| pubmed-article:16855011 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16855011 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:16855011 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16855011 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16855011 | pubmed:pagination | 504-10 | lld:pubmed |
| pubmed-article:16855011 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:meshHeading | pubmed-meshheading:16855011... | lld:pubmed |
| pubmed-article:16855011 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16855011 | pubmed:articleTitle | Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer. | lld:pubmed |
| pubmed-article:16855011 | pubmed:affiliation | Department of Surgery and Clinical Oncology, Osaka University, Suita, Osaka, Japan. | lld:pubmed |
| pubmed-article:16855011 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16855011 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16855011 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:16855011 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16855011 | lld:pubmed |
